A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801)

被引：1

作者：

Gomez, H.

Neciosup, S.

Tosello, C.

Mano, M.

Bines, J.

Ismael, G.

Santi, P. X.

Pinczowsky, H.

Neron, Y.

Fanelli, M.

Fein, L.

Sampaio, C.

Lerzo, G.

Capo, A.

Zarba, J. J.

Blajman, C.

Varela, M. S.

Martinez-Mesa, J.

Werutsky, G.

Barrios, C. H.

机构：

[1] Inst Nacl Enfermedades Neoplas, Lima, Peru

[2] Inst Brasileiro Controle Canc, Sao Paulo, Brazil

[3] Univ Sao Paulo, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[4] Inst Nacl Canc Brasil, Rio De Janeiro, Brazil

[5] Fundacao Doutor Amaral Carvalho, Jau, Brazil

[6] Fac Med ABC, Santo Andre, Brazil

[7] Ctr Pesquisas Oncol Santa Catarina, Florianopolis, SC, Brazil

[8] Hosp AC Camargo Fund Antonio Prudente, Sao Paulo, Brazil

[9] Ctr Oncol Rosario, Rosario, Argentina

[10] Clin Amo, Salvador, BA, Brazil

[11] Invest Clin Ciudad Buenos Aires, Buenos Aires, DF, Argentina

[12] Fdn Ctr Oncol Integrac Reg, Mendoza, Argentina

[13] Ctr San Roque, San Miguel De Tucuman, Argentina

[14] ISIS Clin Especializada, Santa Fe, Santa Fe, Argentina

[15] CER Inst Med, Buenos Aires, DF, Argentina

[16] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, RS, Brazil

[17] Hosp Sao Lucas, PUCRS Sch Med, Porto Alegre, RS, Brazil

来源：

CANCER RESEARCH | 2013年 / 73卷

关键词：

D O I：

10.1158/0008-5472.SABCSI3-P4-12-26

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P4-12-26

引用

页数：2